Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilteritinib maintenance after induction/consolidation in FLT3-ITD AML first complete remission
2016-001643-39Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Gilteritinib maintenance with Placebo maintenance (2 arms). Primary endpoint: Relapse-free survival. Started Nov 2016; status: completed.
02
Drugs
gilteritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2016-001643-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001643-39.